Physician profile
Timothy Yang
NPI 1326569229
$693.39
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $73.77 · 2022: $12.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $312.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $129.03 | 2019-2020 | |
| Alkermes, INC. | $91.27 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $29.34 | 2020 | |
| Vanda Pharmaceuticals INC. | $24.11 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.55 | 2019 | |
| Novo Nordisk INC | $14.83 | 2019 | |
| Lundbeck LLC | $14.05 | 2019 | |
| Corium, LLC | $12.55 | 2022 | |
| Neurocrine Biosciences, INC. | $11.32 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.